181 related articles for article (PubMed ID: 15008344)
1. Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis.
Costa M; Passos XS; Miranda AT; de Araújo RS; Paula CR; Silva Mdo R
Mycopathologia; 2004 Jan; 157(1):43-7. PubMed ID: 15008344
[TBL] [Abstract][Full Text] [Related]
2. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
3. [Comparative study of itraconazole and fluconazole therapy in vaginal candidosis].
Vacheva-Dobrevski R; Kovachev S; Nacheva A; Stoev S; Vasilev N
Akush Ginekol (Sofiia); 2004; 43(1):20-3. PubMed ID: 15168649
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
[TBL] [Abstract][Full Text] [Related]
5. Terbinafine versus itraconazole and fluconazole in the treatment of Vulvovaginal candidiasis.
Ferahbas A; Koc AN; Uksal U; Aygen E; Mistik S; Yildiz S
Am J Ther; 2006; 13(4):332-6. PubMed ID: 16858169
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon.
Ghaddar N; Anastasiadis E; Halimeh R; Ghaddar A; Dhar R; AlFouzan W; Yusef H; El Chaar M
BMC Infect Dis; 2020 Jan; 20(1):32. PubMed ID: 31931738
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of itraconazole versus fluconazole in vaginal candidiasis.
Akhtar S; Masood S; Tabassum S; Rizvi DA
J Pak Med Assoc; 2012 Oct; 62(10):1049-52. PubMed ID: 23866445
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of resistance and sensitivity of 1 200 strains of vulvovaginal candidiasis in China to five common antifungal drugs].
Fan LY; Liu ZH; Bai XN; Zong X
Zhonghua Fu Chan Ke Za Zhi; 2022 Aug; 57(8):601-607. PubMed ID: 36008287
[No Abstract] [Full Text] [Related]
9. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
[TBL] [Abstract][Full Text] [Related]
10. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials.
Pitsouni E; Iavazzo C; Falagas ME
Am J Obstet Gynecol; 2008 Feb; 198(2):153-60. PubMed ID: 18068146
[TBL] [Abstract][Full Text] [Related]
11. Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis.
Zhu Y; Shan Y; Fan S; Li J; Liu X
Mycopathologia; 2015 Feb; 179(1-2):111-8. PubMed ID: 25322705
[TBL] [Abstract][Full Text] [Related]
12. Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.
Sherry L; Kean R; McKloud E; O'Donnell LE; Metcalfe R; Jones BL; Ramage G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696240
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.
Sojakova M; Liptajova D; Borovsky M; Subik J
Mycopathologia; 2004 Feb; 157(2):163-9. PubMed ID: 15119851
[TBL] [Abstract][Full Text] [Related]
14. Molecular typing and in vitro fluconazole susceptibility of Candida species isolated from diabetic and nondiabetic women with vulvovaginal candidiasis in India.
Lattif AA; Mukhopadhyay G; Banerjee U; Goswami R; Prasad R
J Microbiol Immunol Infect; 2011 Jun; 44(3):166-71. PubMed ID: 21524609
[TBL] [Abstract][Full Text] [Related]
15. Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis.
Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Tamaya T
Chemotherapy; 1998; 44(5):364-8. PubMed ID: 9732153
[TBL] [Abstract][Full Text] [Related]
16. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis.
Lynch ME; Sobel JD; Fidel PL
J Med Vet Mycol; 1996; 34(5):337-9. PubMed ID: 8912167
[TBL] [Abstract][Full Text] [Related]
17. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.
Bitew A; Abebaw Y
BMC Womens Health; 2018 Jun; 18(1):94. PubMed ID: 29902998
[TBL] [Abstract][Full Text] [Related]
18. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis.
Fan SR; Liu XP
Mycoses; 2011 Nov; 54(6):501-5. PubMed ID: 20406393
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis.
Woolley PD; Higgins SP
Br J Clin Pract; 1995; 49(2):65-6. PubMed ID: 7779645
[TBL] [Abstract][Full Text] [Related]
20. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis.
Fan S; Liu X; Wu C; Xu L; Li J
Mycopathologia; 2015 Feb; 179(1-2):95-101. PubMed ID: 25416649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
